Pipeline

Overview

Silenseed is utilizing its proprietary LODER platform to enable treatment of cancers triggered by previously “undruggable” proteins. The LODER Platform, with its local and continuous drug delivery properties, provides a safe and effective strategy that can be applied to the treatment of different types of solid tumors.

Research

Preclinical

Phase 1

Phase 2

Phase 3

NDA

KRAS-LODER
Pancreas Cancer- Current stage: Phase 2 Clinical Trials
60
PT-LODER
Prostate Cancer- Current stage: Preclinical
40
GBM-LODER
Brain Cancer- Current stage: Research
40